Medibio Limited
TrivarX Limited, a health technology company, engages in the development of AI-driven, scientifically-based devices for screening and diagnosis of behavioral health conditions in Australia and the United States. The company offers mental well-being solutions for businesses through corporate health product; and develops products for healthcare provider market. The company was formerly known as Med… Read more
Medibio Limited (MDBIF) - Net Assets
Latest net assets as of June 2025: $12.65 Million USD
Based on the latest financial reports, Medibio Limited (MDBIF) has net assets worth $12.65 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($13.48 Million) and total liabilities ($831.22K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $12.65 Million |
| % of Total Assets | 93.84% |
| Annual Growth Rate | 3.12% |
| 5-Year Change | -22.93% |
| 10-Year Change | 48.95% |
| Growth Volatility | 71.72 |
Medibio Limited - Net Assets Trend (2001–2025)
This chart illustrates how Medibio Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Medibio Limited (2001–2025)
The table below shows the annual net assets of Medibio Limited from 2001 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $12.65 Million | +27.89% |
| 2024-06-30 | $9.89 Million | +55.94% |
| 2023-06-30 | $6.34 Million | -10.72% |
| 2022-06-30 | $7.11 Million | -56.71% |
| 2021-06-30 | $16.42 Million | +30.19% |
| 2020-06-30 | $12.61 Million | +46.54% |
| 2019-06-30 | $8.60 Million | -38.48% |
| 2018-06-30 | $13.99 Million | +5.05% |
| 2017-06-30 | $13.31 Million | +56.74% |
| 2016-06-30 | $8.49 Million | -6.77% |
| 2015-06-30 | $9.11 Million | +236.17% |
| 2014-06-30 | $2.71 Million | +6.78% |
| 2013-06-30 | $2.54 Million | +3.84% |
| 2012-06-30 | $2.44 Million | +107.58% |
| 2011-06-30 | $1.18 Million | +7.29% |
| 2010-06-30 | $1.10 Million | -55.41% |
| 2009-06-30 | $2.46 Million | -56.63% |
| 2008-06-30 | $5.68 Million | +201.61% |
| 2007-06-30 | $1.88 Million | -16.68% |
| 2006-06-30 | $2.26 Million | -49.09% |
| 2005-06-30 | $4.44 Million | -8.67% |
| 2004-06-30 | $4.86 Million | -5.68% |
| 2003-06-30 | $5.15 Million | -14.89% |
| 2002-06-30 | $6.05 Million | +0.06% |
| 2001-06-30 | $6.05 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Medibio Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10210906700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $109.96 Million | 869.08% |
| Other Comprehensive Income | $6.60 Million | 52.20% |
| Total Equity | $12.65 Million | 100.00% |
Medibio Limited Competitors by Market Cap
The table below lists competitors of Medibio Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ADP - Dusseldorf Stock Exchang
DU:W7L
|
$1.02 Million |
|
Thai Mui Corporation Public Company Limited
BK:THMUI
|
$1.02 Million |
|
Cascadero Copper Corporation
PINK:CCEDF
|
$1.02 Million |
|
CONOCOPHILLIPS - Dusseldorf Stock Exchang
DU:YCP
|
$1.02 Million |
|
Ceprocim SA
RO:CEPO
|
$1.02 Million |
|
CWTH BK AUSTRALIA
MU:CWW
|
$1.02 Million |
|
Cosmo Metals Ltd
AU:CMO
|
$1.02 Million |
|
Advent Technologies Holdings Inc
NASDAQ:ADN
|
$1.02 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medibio Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 9,893,474 to 12,652,377, a change of 2,758,903 (27.9%).
- Net loss of 943,231 reduced equity.
- Other comprehensive income increased equity by 322,694.
- Other factors increased equity by 3,379,440.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-943.23K | -7.45% |
| Other Comprehensive Income | $322.69K | +2.55% |
| Other Changes | $3.38 Million | +26.71% |
| Total Change | $- | 27.89% |
Book Value vs Market Value Analysis
This analysis compares Medibio Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.08x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-06-30 | $9.54 | $0.00 | x |
| 2002-06-30 | $5.57 | $0.00 | x |
| 2003-06-30 | $3.41 | $0.00 | x |
| 2004-06-30 | $2.52 | $0.00 | x |
| 2005-06-30 | $2.05 | $0.00 | x |
| 2006-06-30 | $0.75 | $0.00 | x |
| 2007-06-30 | $0.48 | $0.00 | x |
| 2008-06-30 | $0.95 | $0.00 | x |
| 2009-06-30 | $0.38 | $0.00 | x |
| 2010-06-30 | $0.16 | $0.00 | x |
| 2011-06-30 | $0.10 | $0.00 | x |
| 2012-06-30 | $0.12 | $0.00 | x |
| 2013-06-30 | $0.09 | $0.00 | x |
| 2014-06-30 | $0.08 | $0.00 | x |
| 2015-06-30 | $0.18 | $0.00 | x |
| 2016-06-30 | $0.08 | $0.00 | x |
| 2017-06-30 | $0.11 | $0.00 | x |
| 2018-06-30 | $0.07 | $0.00 | x |
| 2019-06-30 | $0.77 | $0.00 | x |
| 2020-06-30 | $0.29 | $0.00 | x |
| 2021-06-30 | $0.22 | $0.00 | x |
| 2022-06-30 | $0.07 | $0.00 | x |
| 2023-06-30 | $0.04 | $0.00 | x |
| 2024-06-30 | $0.03 | $0.00 | x |
| 2025-06-30 | $0.03 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medibio Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -7.45%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -83.55%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 1.07x
- Recent ROE (-7.45%) is above the historical average (-75.63%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | 3.00% | 133.08% | 0.02x | 1.12x | $-436.18K |
| 2002 | 12.59% | 488.42% | 0.02x | 1.16x | $155.85K |
| 2003 | 1.55% | 138.52% | 0.01x | 1.06x | $-435.26K |
| 2004 | -46.99% | -6210.96% | 0.01x | 1.06x | $-2.77 Million |
| 2005 | -41.21% | -1617.34% | 0.02x | 1.05x | $-2.27 Million |
| 2006 | -34.44% | -4533.35% | 0.01x | 1.08x | $-1.00 Million |
| 2007 | -75.98% | -17111.58% | 0.00x | 1.10x | $-1.62 Million |
| 2008 | -82.06% | 0.00% | 0.00x | 1.09x | $-5.22 Million |
| 2009 | -123.33% | 0.00% | 0.00x | 1.11x | $-3.28 Million |
| 2010 | -300.80% | -226748.21% | 0.00x | 1.28x | $-3.41 Million |
| 2011 | -273.46% | -1095.12% | 0.09x | 2.78x | $-3.34 Million |
| 2012 | -136.11% | -6349.51% | 0.01x | 2.24x | $-3.57 Million |
| 2013 | -43.21% | -5703.14% | 0.00x | 2.13x | $-1.35 Million |
| 2014 | -15.80% | 0.00% | 0.00x | 1.86x | $-699.36K |
| 2015 | -87.73% | -3133.24% | 0.02x | 1.67x | $-8.90 Million |
| 2016 | -104.57% | -48012.69% | 0.00x | 2.11x | $-9.73 Million |
| 2017 | -62.13% | -35812.05% | 0.00x | 1.45x | $-9.60 Million |
| 2018 | -116.54% | -7956.14% | 0.01x | 1.36x | $-17.70 Million |
| 2019 | -76.55% | -1806.51% | 0.03x | 1.55x | $-7.45 Million |
| 2020 | -30.71% | -2900.68% | 0.01x | 1.11x | $-5.13 Million |
| 2021 | -9.06% | -117.65% | 0.07x | 1.06x | $-3.13 Million |
| 2022 | -178.95% | -1264.69% | 0.12x | 1.19x | $-13.43 Million |
| 2023 | -48.40% | -319.70% | 0.12x | 1.27x | $-3.70 Million |
| 2024 | -12.50% | -139.18% | 0.08x | 1.12x | $-2.23 Million |
| 2025 | -7.45% | -83.55% | 0.08x | 1.07x | $-2.21 Million |
Industry Comparison
This section compares Medibio Limited's net assets metrics with peer companies in the Health Information Services industry.
Industry Context
- Industry: Health Information Services
- Average net assets among peers: $171,670,176
- Average return on equity (ROE) among peers: -102.33%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Medibio Limited (MDBIF) | $12.65 Million | 3.00% | 0.07x | $1.02 Million |
| Accolade, Inc. (ACCD) | $390.85 Million | -12.96% | 0.22x | $448.32 Million |
| Achiko AG (ACHKF) | $-625.49K | 0.00% | 0.00x | $314.42K |
| Ascom Holding AG (ACMLF) | $71.10 Million | 9.14% | 1.86x | $152.13 Million |
| Accelera Innovations Inc (ACNV) | $-6.40 Million | 0.00% | 0.00x | $5.72K |
| Aclarion Inc (ACON) | $970.06K | -720.88% | 1.19x | $1.93 Million |
| Alternate Health Corp (AHGIF) | $-13.82K | 0.00% | 0.00x | $6.50K |
| AI/ML Innovations Inc (AIMLF) | $-1.77 Million | 0.00% | 0.00x | $6.84 Million |
| NetraMark Holdings Inc. (AINMF) | $1.83 Million | -284.61% | 0.19x | $70.13 Million |
| AMJ Global Technology (AMJT) | $-118.08K | 0.00% | 0.00x | $10.99 Million |
| American Well Corp (AMWL) | $1.26 Billion | -13.99% | 0.15x | $78.48 Million |